Introduction

Adjuvant
In the mid 1950s, we started to have a much better understanding of the biological mechanisms of establishment of metastases and the role of regional lymph nodes as an effective barrier to tumor spread, because malignant cells have been observed in the bloodstream (Fisher, Turnbull, 1955) . Early studies with adjuvant chemotherapy after surgery in solid tumors (breast adenocarcinoma implanted in mice) began in 1957 (Shapiro, Fugman, 1957) . Based on these findings, Bernard Fisher and colleagues began in 1958, the first collaborative study with the objective of evaluating the response to systemic administration of perioperative chemotherapy in patients with operable breast cancer (Fisher et al, 1958) . Good results were obtained in relation to disease-free interval and overall survival in premenopausal women (Fisher et al, 1968) . Similar results were also observed by other authors, with the use of multidrug therapy (cyclophosphamide, methotrexate and fluorouracil (CMF) with or without prednisone) in advanced breast cancer (BC) (Canellos et al, 1974 , Bonadonna et al, 1976 . Therefore, the addition of adjuvant polychemotherapy in BC showed gain by controlling survival of micrometastases in patients with lymph nodes affected by cancer or not (Fisher et al, 1975; Bonadonna et al, 1976 ; Early Breast Cancer Trialists Collaborative Group (EBCTCG ), 1988; Bonadonna, Valagussa, 1983 ,1987 , Henderson, 1987 , Fisher et al, 1989 Bonadonna et al, 1995; Mansour et al, 1998 , Carlson et al, 2000 and NIH 2000).
Neoadjuvant therapy
Neoadjuvant chemotherapy is defined as a treatment option where chemotherapy is introduced before local treatment, either surgery or radiotherapy (Bear, 1998) . This was introduced by De Lena et al (1978) who administered adriablastin and vincristine in 110 women with advanced BC, achieving response rates of 70% partial. The biological rationale for using neoadjuvant chemotherapy was based on observations in animal models where the removal of primary tumor growth accelerated due to changes in metastatic tumor kinetics, suggesting that growth factors derived from tumor influence the 237 pharmacology, activation and inactivation of drugs, modification of specific targets and regulatory pathways of apoptosis) (Leonessa et al, 2003 , Riddick et al, 2005 . Identification of factors that affect cell metabolism, which are related to drug resistance, will enable the identification of which patients are at particular risk of treatment failure. Among the biochemical and molecular mechanisms of drug resistance, we stress: changes in the activity of topoisomerase II, alterations in the DNA repair mechanism, overexpression of P-glycoprotein; high intracellular concentrations of enzymes purification of cellular metabolism -among them enzymes the family of glutathione S-transferases (GSTs) and changes in the mechanisms of signaling via c-Jun N-terminal kinase 1 (JNK1) -and "apoptosis signal-regulating kinase (ASK1) required for activation of the" mitogenactivated protein (MAP kinases) in apoptosis and cellular restoration. These pathways are also mediated by proteins encoded by genes of GSTs (O'Brien, Tew, 1996; Burg, Mulder, 2002 , L'Ecuyer et al, 2004 ). Different response rates to particular chemotherapy regimens, as observed in patient groups with the same biological characteristics and stage, suggest the existence of different mechanisms of drug resistance, probably induced by genetic alterations (Hayes, Pulford, 1995 ; O'Brien , Tew, 1996; Pakunlu et al, 2003) . Among the mechanisms of purification of cellular metabolism involved in the inactivation of toxic substances to the cell there is the action of the enzyme family of GSTs in phase II metabolism of cell purification. The first evidence of their involvement in resistance to drugs used in chemotherapy have emerged from research published by scientific groups Schisswelbauer et al (1990), Tew (1994) and Hayes, Pulford, (1995) . However, the relationship between GSTs and resistance to chemotherapy remains inconsistent (Riddick et al, 2005) . This mechanism of resistance is related to the ability to regulate the action of enzymes involved in catalyzing electrophilic compounds harmful to cells from activation by cytochrome P-450 1A1 and 1B1 (Phase I). These compounds in turn are substrates for phase II enzyme systems, represented here by the family of GSTs, which are involved on two fronts in the process of drug resistance: production of protective enzymes of metabolism and cellular apoptotic processes via inhibition of JNK1 and ASK1 (Townsed, , Hamada et al, 1994 Tew, 1994 
Glutathione S-transferases (GSTs)
The family of GSTs consists of eight classes termed cytosolic and symbolized by the Greek alphabet: Alpha, Kappa, Mu, Omega, Pi, Sigma, Theta and Zeta. They are highly polymorphic, with about 30% homology between their base sequences. Each of these classes has several alleles that reach 50% similarity between their base sequences, and are able to produce enzymes of phase II cell purification. Cellular purification occurs through the ability to regulate the action of protein kinases involved in the catalysis of electrophilic compounds harmful to cells (xenobiotics) from the activation by cytochrome P-450 1A1 and 1B1, such as genotoxic chemical carcinogens and cytotoxic agents chemotherapeutic drugs and their metabolites by means of connection to glutathione ( Fig. 1) (Townsed, Cowan, 1989 , Shea et al, 1990 Tew, 1994 , Shimada et al, 1996 Townsend, Tew, 2003a, b; Daly, 2003) . The enzymes of the GST family represents about 5 to 10% of all cellular proteins (Burg, Mulder, 2002) . Studies have shown that the GST enzyme complex participates in the JNK1 and ASK1 pathways necessary for activation of MAP kinase signaling processes involved in apoptosis and cellular restoration. They also participate in and catalyze the conjugation of electrophilic compounds and free radicals to the tri-peptide glutathione (γ-glu-cys-gly, or GSH), produced by GSH-reductase. Thus, they become less chemically reactive and more soluble, and its excretion facilitated by membrane enzyme complexes, among which stands out the GP1 enzyme encoded by the MRP1 gene family of ABC transporters (Arrick, Nathan, 1984; Townsed Cowan, 1989 , Hamada et al, 1994 Tew, 1994 . GSH may present itself in several ways, most commonly its reduced sulfhydryl which is related to reactions with substances or reduced-oxide reactions with electrophilic substances. These reactions may be reversible or irreversible, spontaneous or mediated by the enzymes of the family of GSTs (Arrick, Nathan, 1984 ; O'Brien, Tew, 1996; Burg, Mulder, 2002) . GSH has four functions in the anti-cancer thera p y : c e l l p r o t e c t i o n b y b l o c k a d e o f t o x i c substances to the cell, mediating the formation of toxic to cells, cellular targeting, allowing the efflux and influx of substances through association with enzyme systems membrane and therapeutic interaction through changes in the effectiveness of certain drugs (Arrick, Nathan, 1984) . Among the substrates for the cytosolic enzymes of the family of GSTs are anti-neoplastic drugs such as melphalan, chlorambucil, adriamycin, cyclophosphamide, and platinum salts among others (Table 1) Table 1 . Nonsteroidal anti-neoplastic agents associated with increased levels of GST and cellular resistance.
Cytotoxic and carcinogenic substances from the environment such as tobacco, alcohol and red meat, which are possibly related tocarcinogenesis in various organs such as breast, bladder and colon are also substrates for the enzymes of the GST family of
The glutathione S-transferases (GSTs) and breast cancer
The classes of GSTs are related to the BC classes Alpha, Theta, and Pi Mu. In this review we approach the last three, as they are most frequently studied and their analysis has provided further information in relation to adjuvant chemotherapy and CM. The proteins that belong to the Mu class are encoded by a group of genes located on chromosome 1 (GSTM 1-5). These genes are related to various diseases and susceptibility to various forms of cancer (Townsend, Tew, 2003a) . The GSTM1 gene (Genbank access number AY532926) is the most studied and has four different allelic forms (GSTM 1 * A, B 1 * 1 * 1 * 0 null and Ax2 that are related to a variety of malignancies, as lung, colorectal, oropharyngeal, bladder and breast cancers (Bell et The enzymes encoded by the gene GSTM1 catalyze the conjugation of electrophilic compounds and free radicals by GSH and still exert an inhibitory effect on apoptosis via ASK1, independent of its catalytic action. This inhibition occurs while the enzyme complexes of GSTM1/ASK1 are related. In the presence of high concentrations of oxidereactive substances, this complex dissociates, releasing enzymes to ASK1 phosphorylation and signaling of apoptosis (Fig. 2) (Cho et al, 2001 ). The GSTM1 null genotype polymorphism results from the absence of the two alleles that determine gene expression. Thus, individuals with this genotype do not have the capacity to produce the enzymes necessary to catalyze the conjugation with GSH. Moreover, they also do not synthesize the proteins that coalesce to the ASK1 pathway proteins necessary for the inhibition of this pathway of apoptosis (Cho et al, 2001; McIlwain et al, 2006) . The null genotype is present in 40 to 50% of the population (Tew, 1994) , ranging from 22% in Nigeria, 58% among Chinese, 45% in Western Europe and up to 67% in Australia, and it is related to better response to some classes of chemotherapeutic agents against various types of cancer The enzymes produced by gene GSTP1 * A prevails as a marker of carcinogenesis, since they are present in many tumor cells (Townsend, Tew, 2003a) . Their relationship with cell protection is more related to performance in the apoptotic process. While the proteins encoded by the form "wild" GSTP1 * A are related to proteins of the JNK pathway, which inhibits apoptosis. This action will cease as the intensity of the phenomena of stress to which the cell is subjected to increase (fig 2) , a phenomenon that occurs independently of its catalytic action. Since the polymorphic forms do not have the capacity to synthesize proteins that coalesce to JNK pathway enzymes and therefore do not have the ability to inhibit this pathway of apoptosis (Adler et al, 1999, Dang et al, 2005) . Action of GSTM1 and GSTP1 on pathways of apoptosis. While related enzymes ASK1 and JNK1, the proteins encoded by the genes GSTM1 and GSTP1 exert an inhibitory effect of the corresponding pathways of apoptosis. Once exposed to substances oxide -reactive is the dissociation of the complex and phosphorylation of enzymes ASK1 and JNK1 pathways that pass the signal to the apoptosis pathway.
The involvement of enzymes encoded by the gene GSTP1 * A in cell survival processes by catalyzing GSH seems to be a secondary response or consequence of the phenomena of stress to which the cells are submitted and occur in two ways of acting. The first one is mainly related to anthracycline chemotherapy drugs and their substrates when associated with the ABC membrane transporters, responsible for one of the mechanisms of complex cellular efflux of GSH / drug. The second route of action would be on inhibitory complexes GSH / drugs on the enzymes of class GSTP1 * A, stimulating the process of apoptosis (Nakagawa et al, 1988 (Nakagawa et al, .1990 . The presence and distribution of genes encoding the synthesis of enzymes of the family of GSTs in humans are variable. Some individuals do not express the genes GSTM1 and GSTT1, which determine the production of the enzyme purification. It is said that these people have "deleted" these alleles, known as GSTs null. These in turn are unable to promote catalysis of toxic substances with GSH and unable to promote inhibition of protein kinases required for the apoptotic process. Since the class Pi presents a substitution of amino acid isoleucine (Ile) by valine (Val) at codon 105 (GSTP1 * A → GSTP1 * B) This change, either in a strand of DNA (heterozygous) or both strands (homozygous) also makes cells unable to produce their own enzymes catalyzing GSH, which was similar to the GSTs null, and no longer inhibit the JNK apoptosis 1 ( 
P-glycoprotein
The phenomenon of multi-drug resistance was first described in 1970 in ovarian cancer cells derived from Chinese hamsters exposed to increasing concentrations of various chemotherapeutic agents like actinomycin D, anthracyclines, vinca alkaloids and etoposide, until chemo resistant clones emerged (Bield, Riehm, 1970). Subsequently, Riordan and Ling (1979) showed the phenotype of multidrug resistance by measuring a deficit accumulation of cytotoxic drugs in the intracellular environment due to the action of a specific glycoprotein. One of the proteins responsible for determining this resistance phenotype is the Pglycoprotein (Pgp), first described by Juliano and Ling (1976) , responsible for the permeation and elimination of substances through the cell membrane (Carlsen et al, 1976; Riordan, Ling, 1979) . This transmembrane protein has a molecular weight of 170 kd, 1280 amino acids, is encoded by the gene MDR-1 and depends on energy coming from the metabolism of adenosine triphosphate (ATP) (Sauna et al, 2001 ). The MDR -1 gene in humans is located on the long arm of chromosome 7 (7 q 21) consisting of a central promoter region and 29 exons ranging from 6.3 to 210 kilobases (Bodor et al, 2005) . Pgp is the most investigated of a superfamily called ATP -binding cassette transporters, or ABC multidrug transporters. It is encoded by some genes as MRP-1, MRP-2, MRP-3, MRP-4, MRP-5,MRP-6, MRP-8, BSPE, BCRP (Goldstein, 1996; Scotto, 2003) ABC transporters are characterized functionally by their ability to eliminate antiblastic hydrophilic drugs from the intracellular environment , as shown below (Fig.3) , (Sauna et al, 2001 ). Several drugs are substrates to the protein encoded by MRP's as anthracyclines agents, vinca's alkaloid, taxanes, actinomycin D, among others (Goldstein, 1996) . It consists of a basic structure composed of two transmembrane domains (TMD) associated with two helical domains attached to nucleotides, in a conical shape of 10 nm depth, oriented perpendicular to the cell membrane, as visualized in Fig. 4 (Leonessa, Clarke, 2003) . The three-dimensional shape of Pgp consists of a conical shape with a central pore, with its base open to the extracellular medium and its apex toward the intracellular region, virtually closed when this protein is not active (Leonessa, Clarke, 2003) . The substrates of Pgp diffuse into the inner layers of the cell membrane along the propeller of their domains. With binding of the substrate on Pgp, ATP hydrolysis occurs after the conformational rearrangement of the protein obliterates the internal pore. Simultaneously, there is rotation of the helix, contributing to the decrease in the affinity between substrate and protein, eliminating it from the external environment. (Leonessa, Clarke, 2003) . The mechanism by which Pgp interacts with this wide variety of substrates is still unclear. However, all substrates have in common that they are hydrophobic, have a molecular weight from 300 to 2000 Da; and some carry a positive charge at neutral pH (Sauna et al, 2001 ). The expression of Pgp is not uniform across tissues, occurring both in normal and neoplastic tissues (Goldstein, 1996; Sauna et al, 2001 ) and is expressed physiologically in the bloodbrain barrier, liver, kidneys, intestine, adrenal glands and testicles, functioning to control the absorption, distribution and excretion of xenobiotics (Gottesmann, Pastan, 1993; Ambudkar et al, 1999) . High levels of Pgp are found in renal tumors, liver and colon, low concentrations are identified in bladder tumors, breast cancer and stomach cancer. In tumors that have failed initial treatment, its expression is particularly high, as in breast, ovarian and non-Hodgkin lymphoma (Goldstein, 1996) . Tumors that initially show resistance to drug infusion (primary resistance) to anthracycline derivatives also express high concentrations of P-glycoprotein (Goldstein, 1996) . Pgp expression is and adverse prognostic factor on multivariate analysis, in patients with neuroblastoma and childhood sarcomas (Chan et al, 1990 , Chan et al 1991 , although this has www.intechopen.com not been consistent association (Goldstein, 1996) . The expression of Pgp associated with bcl-2 in acute lymphoblastic leukemia in adults is an independent prognostic factor for diseasefree survival (Del Principe et al, 2003) . In endometrial carcinoma, the immunohistochemical overexpression of Pgp is seen especially in premenopausal patients compared to patients of advanced age (Terek et al, 2003) . In ovarian cancer, overexpression of MDR-1 gene is associated with decreased disease-free survival and tumor progression during chemotherapy (Kavallaris et al, 1996; Raspollini et al, 2005) . In breast carcinoma, the expression of Pgp shows great heterogeneity due to the detection methods and different degrees of their induction by the use of multiple chemotherapeutic agents (Trock et al, 1997; Leonessa, Clarke, 2003) . The expression of Pgp may be quantified by immunohistochemical analysis (IHC) or by use of polymerase chain reaction reverse transverse (RT-PCR) to identify the levels of ribonucleic acid type ( m R N A ) i n o r d e r t o i d e n t i f y i t s p r o t e i n expression (Ro et al, 1990; Leonessa, Clarke, 2003) . In patients with previously untreated breast carcinoma, the detection rates observed by IHC ranged from 0% (Yang et al, 1999 ) to 100% (Del Vecchio et al, 1997) with average rates of 45.9% (Leonessa, Clarke, 2003) . We verified the expression of Pgp mRNA by RT-PCR ranging from 0 to 100% with average rates of 63% (Leonessa, Clarke, 2003) . The comparison between the methods of evaluation shows sensitivity of detection comparable between the two methods, with agreement rates of about 73% between IHC and RT-PCR (Chevillard et al, 1996; Filipits et al, 1996) .
Polymorphism C3435T of the MDR-1 gene
The 26 and plasma levels of digoxin, which reflects its activity in vivo. Individuals with the TT genotype in the intestinal epithelium had significantly higher blood levels of digoxin than individuals with the CC and CT genotype, demonstrating functional differences in their activity and in their expression (Hoffmeyer et al, 2000) . Other authors such as Kim et al (2001) , confirmed these findings through research of this functional polymorphism using the technique of single-strand conformation polymorphism (SSCP) in peripheral blood samples of different populations of Euro-American individuals and African Americans. These authors, using another Pgp substrate, fexofenadine, reported that CC homozygotes had higher rates of serum concentration of this substrate when compared with the TT genotype, also demonstrating functional differences between different polymorphisms of the MDR-1 gene and consequently the expression of Pgp. This scenario has clear implications when considering the therapeutic use of drugs that are substrates related to Pgp and may, depending on the functional action determined by this polymorphism, have different rates of clinical response. Kafka et al. (2003) , showed a significant correlation between the C3435T polymorphism of the MDR-1 gene and partial and complete response to primary chemotherapy with anthracyclines, in patients with locally advanced breast carcinoma. These authors found that the presence of genotype TT was significantly correlated with clinical response, suggesting that the demonstration of this polymorphism could identify tumors sensitive and resistant to anthracyclines, and allow better individualization of therapy.
Summary
Different response rates suggest the existence of different mechanisms of drug resistance. Identification of factors which are related to drug resistance will enable the identification of which patients are at particular risk of treatment failure. Pgp, encoded by the gene MDR-1, is the most investigated of a superfamily called ATPbinding cassette transporters, or ABC multidrug transporters. It has been involved as one of the drug-resistance's mechanisms since 1976. On the other hand, the action of GSTs family as cellular enzymes purification as signaling apoptosis has been studied since 1990's. The whole involvement of these enzymes is not totally clear yet, but seems that together represents a very important resistant mechanism to the chemotherapy treatments. More research is needed in this line of research to better understand these mechanisms.
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